Accordingly, it is not surprising that a leading institution such as Johns Hopkins Medicine is at the forefront of this trend. John Hopkins University was an early participant in the clinical ...

Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical announced that The Johns Hopkins Hospital has performed its first ...

EDAP TMS reported Q2 2023 revenues of $15.52 million, a 0.9% YoY growth that missed estimates. In Q2 2023, HIFU’s total revenue growth stood at 63.6% (YoY). The procedure growth of Focal One shot up ...

This promising new application for Remplir can potentially reduce post-surgical complications from peripheral nerve injury, representing a globally significant commercial opportunity for the Company.

Purpose-built facility secures Convergent's drug product manufacturing at the scale needed to meet late-stage CONV01- clinical studies and commercial demand Expanded partnership designed to drive ...

Although the use of tissue-based gene expression testing for prostate cancer was found to be “highly variable in the United States at the regional level,” distinct regional trajectories of commercial ...

Cleveland Clinic’s commercialization arm, Innovations, has spun off its fifth company this year in a joint project with an existing Cleveland startup. The new company is scooping up cancer diagnostic ...

(NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased ...

Company to invest in further research to strengthen clinical evidence ahead of medium-term U.S. launch with no further FDA approvals needed PERTH, Australia, Nov. 20, 2025 /PRNewswire/ -- Orthocell ...

Profound Medical (PROF) announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the ...